Zoetis announced it has entered into a definitive agreement to acquire the animal genomics business of Neogen Corporation for $160 million, subject to customary closing adjustments. The transaction is designed to strengthen Zoetis’ leadership in Precision Animal Health and accelerate innovation in livestock genomics.
The acquisition aligns with Zoetis’ strategy to drive future livestock innovation through genomics and expand its Precision Animal Health portfolio. By integrating Neogen’s genomic technologies and data solutions, Zoetis aims to enhance its ability to deliver predictive insights, individualized care, and greater value to customers across major livestock and companion animal species.
Neogen’s genomics business serves customers in more than 120 countries and operates five laboratories across the United States, Brazil, Australia, China and the United Kingdom, along with an office in Canada. The unit utilizes a comprehensive genotyping platform that includes fixed array and sequencing technologies, supported by software solutions that enable data-driven decision-making. It holds a leadership position in U.S. beef and dairy genomics, providing scalable genetic testing and advanced insights into animal health, productivity and sustainability.
Zoetis expects the transaction to close in the second half of calendar year 2026, subject to customary closing conditions and regulatory approvals. The company said it is committed to a seamless integration process to ensure continuity for employees and customers while building on Neogen’s established genomics capabilities.
Founded nearly 75 years ago, Zoetis operates in more than 100 countries and develops medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for veterinarians, livestock producers and pet owners. Neogen maintains a presence in over 140 countries, delivering solutions across food safety, livestock and pet health and wellness markets.
KEY QUOTE:
“The addition of Neogen’s genomics business strengthens our commitment to advancing animal health through innovation, data, and technology. As we continue to grow our leading innovative solutions in Precision Animal Health, this acquisition brings complementary capabilities that expand predictive insights and individualized care, enabling us to deliver added value to customers. Together, we are shaping the future of animal health, empowering customers with the tools they need to support healthier animals and sustainable livestock production globally.”
Jamie Brannan, Chief Commercial Officer, Zoetis
